Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Journal Guam.
Press releases published on September 23, 2025
Atsena Therapeutics Announces Dosing Complete for Adults in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis
Pediatric dosing expected to begin in Q4 2025 Pivotal cohort expected to begin enrolling in Q1 2026 BLA submission anticipated in early 2028 Part A results demonstrated efficacy and safety; ATSN-201 on track to be first gene therapy and one-time treatment …
MariMed’s Betty’s Eddies Spreads Importance of Cancer Screening Education and Awareness through Partnership with Keep A Breast Foundation
NORWOOD, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Betty’s Eddies™ announced its third annual collaboration with the Keep A Breast Foundation (“KAB”), furthering its commitment to breast cancer awareness, early screening education, and community support. …
Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025
BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will host a …
Altimmune to Participate in Two Upcoming Investor Conferences
GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the …
Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22
Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22 First disclosure of a novel mechanism of action for the degradation of TEAD by selectively inducing its …
Transpire Bio’s ANDA for Generic Breo® Ellipta® Accepted for Filing By the U.S. FDA
SUNRISE, Fla., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug …
Microbix Assisting EMQN with Second Genetic-Test EQA Program
MISSISSAUGA, Ontario and MANCHESTER, United Kingdom, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and EMQN CIC (EMQN), a global supplier of …
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
FRIENDSWOOD, Texas, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized as a Greater Pittsburgh Top Workplace …
SEED Therapeutics Completes $30 Million Series A-3 Financing
KING OF PRUSSIA, Pa., Sept. 23, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable disease drivers, today announced the successful …
BPGbio Welcomes Back NAi Interrogative Biology® Platform Co-Inventor Slava Akmaev, Ph.D., as Chief Operating Officer and Chief AI Officer
Seasoned AI-Biotech veteran strengthens the company’s leadership in AI and mitochondrial medicine Co-Inventor of AI platform boosts company’s momentum in advancing late-stage assets to commercialization BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- BPGbio Inc …
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological …
Tilray Beverages Unveils New Fall Seasonal Craft Brews with Oktoberfest-Inspired Lineup
ATLANTA, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a leading global lifestyle and consumer packaged goods company, is raising a stein to the season with a festive lineup of Oktoberfest-inspired craft brews from …
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically meaningful and durable antidepressant effects, which are …
BioNTech veranstaltet am 1. Oktober 2025 zweiten „AI Day“ als eine Ausgabe der „Innovation Series“
MAINZ, Deutschland, 23. September 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“) richtet zusammen mit ihrem Tochterunternehmen für künstliche Intelligenz (artificial intelligence, „AI“), InstaDeep Ltd. („InstaDeep“), am Dienstag, den 1. …
BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025
MAINZ, Germany, September 23, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host its second AI Day, an edition of BioNTech’s “Innovation Series”, at …
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announced the Closing of Their Previously Announced Business Combination on September 22, 202…
Semnur’s shares of common stock and warrants are expected to trade on the OTC Markets on September 23, 2025 under the ticker symbols “SMNR” and “SMNRW”, respectively. Scilex (together with its affiliates) owns approximately 87.5% of Semnur common stock …
NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor
SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of …
2025 InnoMatch Tech-Matching Fair Opens in Shanghai to Push Global Sci-Tech Cooperation
SHANGHAI, Sept. 23, 2025 (GLOBE NEWSWIRE) -- The 2025 InnoMatch Tech-Matching Fair kicked off in Shanghai on September 21 as a key part of the 18th Pujiang Innovation Forum. Focusing on demand-driven project solicitation, talent scouting, and capital …
Santhera gibt die Finanzergebnisse für das erste Halbjahr 2025 bekannt und informiert über aktuelle Unternehmensentwicklungen
Ad-hoc-Mitteilung gemäss Art. 53 LR Am 23. September 2025 um 14:00 Uhr MESZ / 13:00 Uhr BST / 08:00 Uhr EDT findet eine Telefonkonferenz statt. Einzelheiten finden Sie am Ende dieser Pressemitteilung. Pratteln, Schweiz, 23. September 2025 – Santhera …